About Ethris
Ethris is a company based in Planegg (Germany) founded in 2009. Ethris has raised $31.3 million across 5 funding rounds from investors including Gates Foundation, European Union and EU4Health. The company has 59 employees as of December 31, 2023. Ethris operates in a competitive market with competitors including Insitro, BridgeBio, Moderna, GSK and ATAI, among others.
- Headquarter Planegg, Germany
- Employees 59 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ethris Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.3 M (USD)
in 5 rounds
-
Latest Funding Round
$11.22 M (USD), Grant
May 09, 2025
-
Investors
Gates Foundation
& 3 more
-
Employee Count
59
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Ethris
Unlock access to complete
Funding Insights of Ethris
Ethris has successfully raised a total of $31.3M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $11.22 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ethris
Ethris has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, European Union and EU4Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
EU4Health is focused on promoting health policies across Europe.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Ethris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ethris
Investment portfolio details for Ethris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ethris
Detailed financials for Ethris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ethris Comparisons
Peer comparison for Ethris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ethris
Ethris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Moderna, GSK and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Ethris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ethris
Complete news archive for Ethris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ethris
Ethris was founded in 2009 and raised its 1st funding round 10 years after it was founded.
Ethris is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Ethris is a funded company, having raised a total of $31.3M across 5 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Ethris is 59.
Ethris was founded in 2009 and is based in Planegg, Germany, where operations focus on biotechnology for mRNA-based treatments. Two proprietary platforms are employed: one for stabilized non-immunogenic mRNA transcript therapy and another for targeted RNA delivery systems. These enable chemical modifications to avoid immune responses and support protein expression. The pipeline targets COVID-19, respiratory conditions, and primary ciliary dyskinesia.
Ethris's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Ethris has 4 investors. Key investors include Gates Foundation, European Union, EU4Health, and Laureus Capital.